C D DE LANGEN
Overview
Explore the profile of C D DE LANGEN including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
165
Citations
275
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
3.
4.
Blaauw Y, Tieleman R, Brouwer J, VAN DEN BERG , de Kam P, DE LANGEN C, et al.
Pacing Clin Electrophysiol
. 1999 Dec;
22(11):1656-67.
PMID: 10598970
Atrial fibrillation (AF) shortens the atrial effective refractory period (AERP). To investigate the role of the autonomic nervous system during this so-called electrical remodeling of the atria (ERA) and during...
5.
Tieleman R, Blaauw Y, van Gelder I, DE LANGEN C, de Kam P, Grandjean J, et al.
Circulation
. 1999 Oct;
100(17):1836-42.
PMID: 10534473
Background: Atrial fibrillation (AF) induces electrical remodeling, which is thought to be responsible for the low success rate of antiarrhythmic treatment in AF of longer duration. Electrical remodeling seems to...
6.
Hoekstra A, DE LANGEN C, Nikkels P, Korteling B, Bel K, Crijns H
J Interv Card Electrophysiol
. 1999 Feb;
2(4):383-9.
PMID: 10027126
A prototype steerable 8.5 F bipolar catheter fitted with a feedback thermocouple was tested in 7 anaesthetized pigs (30 kg) guided by the electrocardiogram in order to modify the AV...
7.
van den Berg M, van de Ven L, Witting W, Crijns H, Haaksma J, Bel K, et al.
Jpn Heart J
. 1998 Mar;
38(6):841-8.
PMID: 9486937
Despite their widespread use in atrial fibrillation, the effects of beta-adrenoceptor blockers on atrial and atrioventricular (AV) nodal refractoriness, and atrial fibrillatory rate during atrial fibrillation have been incompletely characterised....
8.
Buikema H, Pinto Y, Geel P, Rooks G, DE LANGEN C, de Graeff P, et al.
J Cardiovasc Pharmacol
. 1997 May;
29(5):684-91.
PMID: 9213213
Utibapril is an angiotensin-converting enzyme (ACE) inhibitor with a proposed tissue-specific inhibitory profile. This implies that at a certain dose, utibapril should be able to inhibit tissue ACE activity without...
9.
Tuininga Y, DE LANGEN C, Crijns H, Wiesfeld A, Mook P, Bel K, et al.
Pacing Clin Electrophysiol
. 1996 May;
19(5):802-10.
PMID: 8734747
Ventricular arrhythmias remain a major problem, in particular in patients with left ventricular dysfunction or heart failure. In this group of patients, Class I drugs were shown to be ineffective,...
10.
Wiesfeld A, DE LANGEN C, Crijns H, Bel K, Hillege H, Wesseling H, et al.
J Cardiovasc Pharmacol
. 1996 Apr;
27(4):594-600.
PMID: 8847879
The electrophysiologic effects of intravenously administered almokalant, a new class III antiarrhythmic drug, in 7 isoflurane-anesthetized pigs after low and high dose were investigated. Low-dose almokalant included bolus infusion of...